

13TH August 2021

To
Department of Corporate Services
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001
Scrip Code: **BSE - 524500**

To
Corporate Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1, G Block,
BKC, Bandra (E), Mumbai 400 051
Scrip Code: **NSE - KILITCH**

Sub: **Outcome of Board Meeting held on 13th August 2021**

Dear Sir/Madam,

In continuation to our letter dated 5th August 2021, we wish to inform you that pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the company, at its meeting held today i.e. 13th August 2021, have considered and approved the following-

1. The Un-audited financial results of the company for the quarter ended 30th June 2021;

In this connection please find enclosed the copy of Un-audited Standalone financial Results of the Company for the quarter ended 30th June 2021 along with Limited Review Report by the Statutory Auditors of the Company as "Annexure-I".

2. The appointment of M/s Suryaprakash Maurya & Co (FRN: 147410W) as the Statutory Auditor of the Company to hold office from the conclusion of 29th AGM till the conclusion of 34th AGM.
3. The Directors Report of the Company along with the Corporate Governance Report and all relevant annexures thereof for the financial year 2020-2021.
4. Decided to convene the 29th Annual General Meeting of the Company on Wednesday, 29th September 2021 at 9.00 A.M. through Video Conference (VC) or Other Audio Visual Means (OAVM)
5. The Notice of the 29th Annual General Meeting for the year ended 31st March 2021.
6. Appointment of M/s. Deep Shukla, Practicing Company Secretary as Scrutinizer to conduct the entire voting process at the 29th AGM of the Company (including e-voting) and to submit the Report for declaration of the results thereof.
7. The Register of Members and Share Transfer Books of the Company shall remain closed from **Thursday, 23rd September 2021 to Wednesday, 29th September 2021** (both days inclusive) pursuant to regulation 42 of the SEBI (Listing Obligation and Disclosure Requirements)





Kilitch Drugs (India) Ltd.

Regulations, 2015 for the purpose of 29th AGM.

The meeting commenced at 12: 30 P.M. and concluded at 4:50 P.M.

The above is for information and dissemination to the public at large.

Thanking You,

Yours Faithfully,

For Kilitch Drugs (India) Limited

Mukund Mehta
(Managing Director)

DIN:00147876

Encl: as above



A. M. GHELANI & COMPANY
CHARTERED ACCOUNTANTS

Limited Review Report on Unaudited Quarterly Consolidated Financial Results of Kilitch Drugs (India) Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,
The Board of Directors of
Kilitch Drugs (India) Limited

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **Kilitch Drugs (india) Limited** ("the Parent"), and its' subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30th June, 2021 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This statement which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether Statement is free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, to the extent applicable.

4. The Statement includes the results of entities as given below:

List of Subsidiaries:


1. Monarchy Healthserve Private Limited
2. Kilitch Estro Biotech PLC – Foreign Subsidiary



A. M. GHELANI & COMPANY
CHARTERED ACCOUNTANTS

5. The Statement includes interim financial results and other financial information in respect of one foreign subsidiary which reflects Total Revenue of Rs. 45.20 Lakhs, Net Profit/(Loss) after Tax of Rs. (141.84) Lakhs and Total Comprehensive Income of Rs. (141.84) Lakhs for the quarter ended 30th June, 2021 as considered in the consolidated financial results. These financial statements have been furnished to us by the management and our opinion on the statement, in so far as it relates to the amounts included in respect of this subsidiary is solely based on such unaudited financial statements as certified by the management. Our conclusion on the Statement is not modified in respect of the above matter.
6. We draw attention to Note 5 of the Statement, which describes the Group's management evaluation of impact of Covid 19 pandemic on the its business, logistics etc. The Management has made reasonable judgements and estimates from internal and external sources of information including economic forecasts, inter alia, in determining carrying amounts of trade receivables, property, plant & equipment, inventories and other financial assets while preparing the financial results as of and for the quarter ended 30th June, 2021. Our conclusion on the Statement is not modified in respect of these matters.
7. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on management certified financial statements referred in paragraph 5 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A. M. Ghelani & Company
Chartered Accountants
Firm Registration No. 103173W


Chintan A. Ghelani
Partner

Membership No. 104391

ICAI UDIN: 21104391AAAAGA4239

Place : Mumbai
Date : 13th August, 2021



KILITCH DRUGS (INDIA) LIMITED
STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2021



Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701
Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

(Rs. In Lakhs)

Sr. No.	Particulars	CONSOLIDATED			
		Three Months Ended		Year Ended	
		30/06/2021	31/03/2021	30/06/2020	31/03/2021
		Unaudited	Audited	Unaudited	Audited
1	Income				
	Net Sales/Income from Operations	1,962.49	1,993.20	1,019.17	6,852.31
	Other Income	105.38	150.73	36.95	266.73
	Total Income	2,067.87	2,143.93	1,056.12	7,119.04
2	Expenses				
	Cost of Materials Consumed	1,637.94	1,144.42	671.10	3,621.91
	Variation in inventories of finished goods, work-in-progress and Stock-in-Trade	(538.61)	(2.50)	51.20	108.81
	Employee Benefit Expenses	140.99	134.80	115.46	523.98
	Finance Cost	12.75	16.15	29.32	75.44
	Depreciation and Amortisation Expenses	44.41	50.36	48.55	198.61
	Export Product Registration/Commission	147.55	245.35	50.20	448.30
	Other expenses	484.25	438.35	242.43	1,630.03
	Total Expenses	1,929.28	2,026.93	1,208.26	6,607.08
3	Profit/(Loss) before Exceptional items (1-2)	138.59	117.00	(152.14)	511.96
4	Exceptional Items	-	-	-	-
5	Profit/(Loss) from ordinary activities before tax (3+4)	138.59	117.00	(152.14)	511.96
6	Less : Tax Expenses				
	Current Income Tax	61.45	25.55	-	166.55
	Deferred Tax	5.18	20.60	(18.77)	(31.25)
7	Profit/(Loss) after tax for the period from continuing operations (5-6)	71.96	70.85	(133.37)	376.66
8	Other Comprehensive Income (after Tax)	149.12	1.02	184.43	522.87
9	Total Comprehensive Income (after taxes) (7+8)	221.08	71.87	51.06	899.53
10	Net Profit / (Loss) attributable to				
	a) Owner of the Company	118.77	70.85	(133.37)	367.11
	b) Non Controlling interest	(46.81)	-	-	9.55
11	Other Comprehensive Income attributable to				
	a) Owner of the Company	149.12	1.02	184.43	522.87
	b) Non Controlling interest	-	-	-	-
12	Total Income attributable to				
	a) Owner of the Company	267.89	71.87	51.06	889.98
	b) Non Controlling interest	(46.81)	-	-	9.55
13	Paid-Up equity share capital (Face Value Rs. 10 per share)	1,556.20	1,549.45	1,547.91	1,549.45
14	Other Equity				11,163.42
15	Earning per share				
	(a) Basic (not annualised)	0.76	0.46	(0.86)	2.37
	(b) Diluted (not annualised)	0.76	0.46	(0.86)	2.37

Notes:

- The above unaudited Consolidated Financial Results of the Group for the quarter ended 30th June, 2021 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 13th August, 2021.
- The Statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.



3. The Company has issued 67,470 Equity Shares under the ESOP scheme at an exercise price of Rs. 10 per equity share during the quarter ended 30th June, 2021.

4. The Group is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.

5. The Group continues to monitor the impact of Covid-19 on its business, including its impact on customers, supply-chain, employees and logistics. The Management has exercised due care and made reasonable judgements and estimates from internal and external sources of information including economic forecasts, inter alia, in determining carrying amounts of trade receivables, property, plant & equipment, inventories and other financial assets while preparing the financial results as of and for the quarter ended 30th June, 2021. The Group based on current estimates expects to recover the carrying amount of the above assets, net of provisions established.

In view of the uncertainties regarding the nature and duration of the ongoing COVID-19 Pandemic, we are unable to predict the future impact on our business operations. However, the Group will continue to closely monitor the situation and take appropriate measures in an attempt to mitigate any adverse impact on its future economic conditions.

The figures for the quarter ended 31st March, 2021 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2021 and unaudited published year to date figures upto the nine months of the relevant financial year which were subject to limited review by the Statutory Auditors.

6.

The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods.

Place: Mumbai
Date: 13th August, 2021



For and on behalf of the Board of Directors

Mukund P. Mehta
Director



A. M. GHELANI & COMPANY
CHARTERED ACCOUNTANTS

Limited Review Report on Unaudited Quarterly Financial Results of Kilitch Drugs (India) Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,
The Board of Directors of
Kilitch Drugs (India) Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Kilitch Drugs (India) Limited** (the 'Company') for the quarter ended 30th June, 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition & measurement principles laid down in the Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules thereafter and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We draw attention to Note 5 of the Statement, which describes the company's management evaluation of impact of Covid 19 pandemic on the its business, logistics etc. The Management has made reasonable judgements and estimates from internal and external sources of information including economic forecasts, inter alia, in determining carrying amounts of trade receivables, property, plant & equipment, inventories and other financial assets while preparing the financial results as of and for the quarter ended 30th June, 2021.

Our conclusion on the Statement is not modified in respect of these matters.



A. M. GHELANI & COMPANY
CHARTERED ACCOUNTANTS

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A. M. Ghelani & Company
Chartered Accountants
Firm Registration No. 103173W



Chintan A. Ghelani
Partner
Membership No. 104391

ICAI UDIN: 21104391AAAAFZ6628

Place : Mumbai
Date : 13th August, 2021

KILITCH DRUGS (INDIA) LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2021


Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701
Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

(Rs. in Lakhs)

Sr. No.	Particulars	STANDALONE			
		Three Months Ended			Year Ended
		30/06/2021	31/03/2021	30/06/2020	31/03/2021
		Unaudited	Audited	Unaudited	Audited
1	Income				
	Net Sales/ Income from operations	1,951.15	2,114.40	1,036.78	7,001.68
	Other Income	148.41	133.83	88.44	419.43
	Total Income	2,099.56	2,248.23	1,125.22	7,421.11
2	Expenses				
	(a) Cost of Materials Consumed	1,079.08	1,254.77	687.51	3,797.46
	(b) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	13.75	(2.50)	51.20	108.81
	(c) Employee Benefit Expenses	140.10	134.38	114.90	521.74
	(d) Finance Cost	12.75	16.15	29.32	75.44
	(e) Depreciation and Amortisation Expenses	23.30	29.23	27.42	114.10
	(f) Export Product Registration/Commission	147.55	245.35	50.20	448.30
	(g) Other Expenses	327.71	438.35	237.82	1,604.43
	Total Expenses	1,744.24	2,115.73	1,198.37	6,670.28
3	Profit / (Loss) before Exceptional items (1-2)	355.32	132.50	(73.15)	750.83
4	Exceptional Items	-	-	-	-
5	Profit / (Loss) from ordinary activities before tax (3+4)	355.32	132.50	(73.15)	750.83
6	Tax Expenses:				
	Current Tax	61.45	25.55	-	166.55
	Deferred Tax	5.18	20.56	(18.73)	(31.26)
7	Net Profit / (Loss) after Tax for the period from Continuing Operations (5-6)	288.69	86.39	(54.42)	615.54
8	Other Comprehensive Income (after tax)	149.11	1.02	184.43	522.87
9	Total Comprehensive Income (after taxes) (7+8)	437.80	87.41	130.01	1,138.41
10	Paid-Up equity share capital (Face Value Rs 10 per share)	1,556.20	1,549.45	1,547.91	1,549.45
11	Other Equity				14,743.96
12	Earnings per share				
	(a) Basic (not annualised)	1.86	0.56	(0.35)	3.98
	(b) Diluted (not annualised)	1.86	0.56	(0.35)	3.98

Notes:

1. The above Unaudited Financial Results of the Company for the quarter ended 30th June 2021 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 13th August, 2021.



2. The Statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

3. The company has issued 67,470 Equity Shares under the ESOP scheme at an exercise price of Rs. 10 per equity share during the quarter ended 30th June, 2021.

4. The Company is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.

5. The Company continues to monitor the impact of Covid-19 on its business, including its impact on customers, supply-chain, employees and logistics. The Management has exercised due care and made reasonable judgements and estimates from internal and external sources of information including economic forecasts, inter alia, in determining carrying amounts of trade receivables, property, plant & equipment, inventories and other financial assets while preparing the financial results as of and for the quarter ended 30th June, 2021. The Company based on current estimates expects to recover the carrying amount of the above assets, net of provisions established.

In view of the uncertainties regarding the nature and duration of the ongoing COVID-19 Pandemic, we are unable to predict the future impact on our business operations. However, the Company will continue to closely monitor the situation and take appropriate measures in an attempt to mitigate any adverse impact on its future economic conditions.


6. The figures for the quarter ended 31st March, 2021 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2021 and unaudited published year to date figures upto the nine months of the relevant financial year which were subject to limited review by the Statutory Auditors.

The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods.

Place : Mumbai
Dated: 13th August, 2021



For and on behalf of the Board of Directors


Mukund P. Mehta
Managing Director

